| Vista previa | Fecha de publicación | Título | Autor(es) | Acceso |
 | 3-ene-2022 | Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease | Orts, Beatriz; Gutierrez, Ana; Madero, Lucía; Sempere, Laura; Francés, Rubén; Zapater, Pedro |  |
 | may-2022 | Cost-Effectiveness of Therapeutic Drug Monitoring of
Anti-TNF Therapy in Inflammatory Bowel Disease: A
Systematic Review | Marquez-Megias, Silvia; nalda-molina, Ricardo; Sanz Valero, Javier; Más-Serrano, Patricio; Diaz-Gonzalez, Marcos; Candela-Boix, Maria Remedios; Ramon-Lopez, Amelia | |
 | ago-2021 | Evaluation of the Predictive Performance of Population
Pharmacokinetic Models of Adalimumab in Patients with
Inflammatory Bowel Disease | Marquez-Megias, Silvia; Ramon-Lopez, Amelia; Más-Serrano, Patricio; Diaz-Gonzalez, Marcos; Candela-Boix, Maria Remedios; nalda-molina, Ricardo | |
 | 2024 | Model-Informed Precision Dosing of adalimumab in patients with inflammatory bowel disease | Márquez Megías, Silvia | |
 | oct-2023 | Population Pharmacokinetic Model of Adalimumab Based on
Prior Information Using Real World Data | Marquez-Megias, Silvia; nalda-molina, Ricardo; Más-Serrano, Patricio; Ramon-Lopez, Amelia | |
 | sep-2024 | Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters | Gutiérrez, Félix ; Fernández González, Marta; Ledesma, Christian; Losada-Echeberría, María; Barrajón-Catalán, Enrique; García-Abellán, Javier; De Stefano, Daria; López, Leandro; Bello-Perez, Melissa; Padilla, Sergio; Masiá, Mar |  |
.png){kind=logo}